New drug shows promise for rare movement disorder

NCT ID NCT02255435

Completed Disease control Sponsor: Biogen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called RTA 408 (omaveloxolone) in 172 people with Friedreich's ataxia, a rare genetic disease that affects movement and coordination. The goal was to see if the drug is safe and can improve exercise ability and daily function. Participants took the drug or a placebo for up to 48 weeks, and researchers measured changes in cycling tests and a rating scale for movement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FRIEDREICH ATAXIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Friedreich ataxia inborn mitochondrial metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FRIEDREICH ATAXIA

Contacts and locations

Locations

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States
Emory University Hospital - Neurology

Atlanta, Georgia, 30329, United States
Medical University Innsbruck

Innsbruck, 6020, Austria
Murdoch Childrens Research Institute

Parkville, Victoria, 3052, Australia
Neurological Institute Carlo Besta

Milan, 20133, Italy
Ohio State University - Neurology

Columbus, Ohio, 43221, United States
UCLA

Los Angeles, California, 90095, United States
USF Ataxia Research Center

Tampa, Florida, 33612, United States
University College of London

London, WC1E 6BT, United Kingdom
University of Florida - Neurology

Gainesville, Florida, 32610, United States
University of Iowa Stead Family Children's Hospital

Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.